Actively Recruiting
Center Without Walls for Imaging Proteinopathies With PET (CW2IP2): Imaging and Diagnostic Assessments
Led by University of Pennsylvania · Updated on 2026-01-07
94
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating new radiotracers designed to detect specific protein deposits in the brains of people with Parkinson's Disease (PD), Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP), Frontotemporal Dementia (FTD), and healthy individuals. This multicenter project involves several universities including the University of Pennsylvania, which serves as the single IRB of Record, and aims to provide key data on the specificity of these imaging agents. The study includes detailed diagnostic assessments to support consistent clinical evaluations across sites. Participants may undergo brain MRI scans and neurological exams, including diagnostic assessments and video interviews. Some sites may perform PET imaging of A-beta amyloid using radiotracers such as Florbetaben (18F) or 11C-PiB, although this imaging is optional and may be conducted within other study protocols. The trial involves regulatory oversight, standardized PET scanner calibration, and common consent and protocol procedures. During the study, participants will have brain MRI scans if a recent scan is not available, neurological examinations, and diagnostic assessments. Clinical consensus diagnoses will be made for all participants. Researchers will collect and analyze clinical and imaging data, with the primary outcome being disease diagnosis evaluated within eight weeks. Participants must be followed for safety, and some may be asked to consent to brain donation after death, except healthy controls. The total participation duration and follow-up details vary by participant.
CONDITIONS
Brief Title
CW2IP2: Imaging and Diagnostic Assessments
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must be between 40 and 85 years old, male or female.
- Participants must provide written informed consent or have a Legally Authorized Representative and Study Partner if unable to consent.
- Clinical diagnoses must be agreed upon by consensus committee for Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy, Frontotemporal Dementia, or healthy control status.
You will not qualify if you...
- Females who are pregnant or breastfeeding at screening.
- Parkinsonism forms other than PD, PSP, and MSA.
- Major psychiatric disorders such as schizophrenia or bipolar disorder.
- History of significant or ongoing alcohol or substance abuse.
- Contraindications or inability to tolerate imaging, arterial line, IV placement, or blood draws.
- Implanted medical devices or other MRI contraindications.
- Current medical conditions that pose safety risks or prevent study participation.
- Refusal to consent to brain donation for non-healthy control participants.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 8 weeks
Participants undergo diagnostic assessments including brain MRI scans and neurologic exams with video interviews to help determine disease diagnosis.
1 to 2 visits depending on MRI availability and assessment scheduling
Trial Site Locations
Total: 1 location
1
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
Research Team
E
Erin o Schubert
R
Refatun Momo
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here